TABLE 2.
Comparison of the baseline characteristics of the four groups.
| Characteristic | Apixaban (N = 50) | Rivaroxaban (N = 110) | Dabigatran (N = 21) | LMWH/VKA (N = 50) |
|---|---|---|---|---|
| Age (yr) | ||||
| Mean | 58 ± 16.3 | 62 ± 11.5 | 64 ± 14.6 | 53 ± 13.6 |
| Range | 24–94 | 29–87 | 32–92 | 19–75 |
| Age category (years), n (%) | ||||
| <75 | 78 | 86.4 | 81.0 | 94.0 |
| ≥75 | 22 | 13.6 | 19.0 | 6.0 |
| Female sex, no. (%) | 50.0 | 42.7 | 52.4 | 50.0 |
| Weight (kg) | ||||
| Mean | 65 ± 11.8 | 77 ± 11.1 | 65 ± 10.2 | 66 ± 1.0 |
| Range | 40–90 | 46–95 | 50–80 | 45–96 |
| BMI (kg/m2) | 23 ± 3.3 | 23 ± 6.4 | 25 ± 3.2 | 24 ± 3.0 |
| Length of hospital stay | ||||
| Mean | 8 ± 6.2 | 9 ± 7.6 | 11 ± 10.1 | 10 ± 8.4 |
| Range | 1–29 | 1–51 | 2–48 | 3–56 |
| Diabetes mellitus, no. (%) | 2.0 | 8.2 | 19.0 | 2.0 |
| Hypertension, no. (%) | 18.0 | 33.6 | 19.0 | 10.0 |
| Type of index event, no. (%) | ||||
| DVT only | 98.0 | 30.0 | 80.9 | 32.0 |
| PE only | 0.0 | 29.1 | 19.1 | 38.0 |
| Both DVT and PE | 2.0 | 40.9 | 0.0 | 30.0 |
BMI: body mass index, API, apixaban; RIV, rivaroxaban; DAB, dabigatran; LMWH/VKA, low molecular weight heparin followed by vitamin K antagonist. DVT, deep vein thrombosis; PE, pulmonary embolism.